Invokana: FDA Warnings on SGLT2 Diabetes Drugs
Sheller, P.C. attorneys are investigating the newer class of diabetes drugs following FDA warnings. ABOUT THE DRUGS Invokana (Invokamet) is a relatively new SGLT2 inhibitor diabetes drug that is intended to be used in combination with diet and exercise to improve glycemic control and lower blood sugar in adults with type 2 diabetes mellitus. When […]
In The New York Times: “Side Effects May Include Lawsuits”
One of the most-read articles in The New York Times regarding pharmaceutical drug product liability and whistleblower lawsuits quotes Stephen Sheller. Side Effects May Include Lawsuits BY DUFF WILSON NEW YORK – FOR decades, antipsychotic drugs were a niche product. Today, they’re the top-selling class of pharmaceuticals in America, generating annual revenue of about $14.6 billion […]
$1.4 Billion Settlement
Philadelphia Attorney Stephen Sheller’s Whistleblower Clients Help Government Recover $1.4 Billion Record Settlement and Criminal Fine in Eli Lilly & Company Zyprexa® Marketing Case Lead Attorney Filed Complaint in 2003 Representing Six Whistleblowers Pharmaceutical giant Eli Lilly & Company (“Lilly”) agreed to pay federal and state governments more than $1.4 billion in January 2009 to […]
